ArticlePloS one2010
The complete multipartite genome sequence of Cupriavidus necator JMP134, a versatile pollutant degrader.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 118 citations in OpenAlex.
- Characterization and Crystal Structure Elucidation of the l-Homoserine O-Succinyltransferase MetXS From Cupriavidus necator H16.Chembiochem : a European journal of chemical biology · 2026Article
- Metabolic interactions enable aerobic degradation of the environmental pollutant BDE-47.The ISME journal · 2026Article
- Insights into genetic determinants of volatile fatty acid catabolism inApplied and environmental microbiology · 2025Article
- Comparative Genomic Assessment of the Cupriavidus necator Species for One-Carbon Based Biomanufacturing.Microbial biotechnology · 2025Article
- Physiology, Heavy Metal Resistance, and Genome Analysis of TwoMicroorganisms · 2025Article
- OxyR-regulated T6SS functions in coordination with siderophore to resist oxidative stress.Microbiology spectrum · 2024Article
- Using Machine Learning to Predict Genes Underlying Differentiation of Multipartite and Unipartite Traits in Bacteria.Microorganisms · 2023Article
- Whole Genome Sequence Analysis ofMicroorganisms · 2023Article
- The benzoyl-CoA pathway serves as a genomic marker to identify the oxygen requirements in the degradation of aromatic hydrocarbons.Frontiers in microbiology · 2023Article
- A genome-scale metabolic model of Cupriavidus necator H16 integrated with TraDIS and transcriptomic data reveals metabolic insights for biotechnological applications.PLoS computational biology · 2022Article
- Natural Chromosome-Chromid Fusion across rRNA Operons in aMicrobiology spectrum · 2022Article
- Article
- Identification of a self-sufficient cytochrome P450 monooxygenase from Cupriavidus pinatubonensis JMP134 involved in 2-hydroxyphenylacetic acid catabolism, via homogentisate pathway.Microbial biotechnology · 2021Article
- Metagenomic Data Assembly - The Way of Decoding Unknown Microorganisms.Frontiers in microbiology · 2021Review
- The multi metal-resistant bacteriumPeerJ · 2021Article
- Widespread distribution ofComputational and structural biotechnology journal · 2021Article
- The Heterotrophic Bacterium Cupriavidus pinatubonensis JMP134 Oxidizes Sulfide to Sulfate with Thiosulfate as a Key Intermediate.Applied and environmental microbiology · 2020Article
- Mycotoxin Biodegradation Ability of the Cupriavidus Genus.Current microbiology · 2020Article
- Applying Statistical Design of Experiments To Understanding the Effect of Growth Medium Components on Cupriavidus necator H16 Growth.Applied and environmental microbiology · 2020Article
- Steroid Degradation in Comamonas testosteroni TA441: Identification of the Entire β-Oxidation Cycle of the Cleaved B Ring.Applied and environmental microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCupriavidus necator JMP134 is a Gram-negative beta-proteobacterium able to grow on a variety of aromatic and chloroaromatic compounds as its sole carbon and energy source. METHODOLOGY/PRINCIPAL
findingsIts genome consists of four replicons (two chromosomes and two plasmids) containing a total of 6631 protein coding genes. Comparative analysis identified 1910 core genes common to the four genomes compared (C. necator JMP134, C. necator H16, C. metallidurans CH34, R. solanacearum GMI1000). Although secondary chromosomes found in the Cupriavidus, Ralstonia, and Burkholderia lineages are all derived from plasmids, analyses of the plasmid partition proteins located on those chromosomes indicate that different plasmids gave rise to the secondary chromosomes in each lineage. The C. necator JMP134 genome contains 300 genes putatively involved in the catabolism of aromatic compounds and encodes most of the central ring-cleavage pathways. This strain also shows additional metabolic capabilities towards alicyclic compounds and the potential for catabolism of almost all proteinogenic amino acids. This remarkable catabolic potential seems to be sustained by a high degree of genetic redundancy, most probably enabling this catabolically versatile bacterium with different levels of metabolic responses and alternative regulation necessary to cope with a challenging environment. From the comparison of Cupriavidus genomes, it is possible to state that a broad metabolic capability is a general trait for Cupriavidus genus, however certain specialization towards a nutritional niche (xenobiotics degradation, chemolithoautotrophy or symbiotic nitrogen fixation) seems to be shaped mostly by the acquisition of "specialized" plasmids. CONCLUSIONS/SIGNIFICANCE: The availability of the complete genome sequence for C. necator JMP134 provides the groundwork for further elucidation of the mechanisms and regulation of chloroaromatic compound biodegradation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.